期刊
HELIYON
卷 7, 期 1, 页码 -出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.heliyon.2021.e06120
关键词
First trimester placental chorion mesenchymal stem cells; Third trimester placental chorion mesenchymal stem cells; Endothelial cells differentiation; Angiogenesis; Myocardial infarction
资金
- Priority Academic Program Development of Jiangsu Higher Education Institutions
- project of Soochow Science and Technology Plan [SYS201761]
- Jiangsu Provincial Medical Youth Talent [QNRC2016770]
- Natural Science Foundation of the Jiangsu Higher Education Institutions of China [19KJB320006]
- Natural Science Foundation of Jiangsu Province [SBK2019040304]
- National Natural Science Foundation of China [81701596, 81402584]
This study aimed to compare the effectiveness of first trimester placental chorion mesenchymal stem cells (FCMSCs) and third trimester placental chorion mesenchymal stem cells (TCMSCs) in the treatment of acute myocardial infarction (AMI). The results showed that FCMSCs exhibited superior in vitro endothelial cell differentiation and angiogenic potential, as well as improved cardiac function, compared to TCMSCs. Increased levels of pro-angiogenesis genes may be the mechanism behind this effect.
Acute myocardial infarction (AMI) is the most critical heart disease. Mesenchymal stem cells (MSCs) have been widely used as a therapy for AMI for several years. The human placenta has emerged as a valuable source of transplantable cells of mesenchymal origin that can be used for multiple cytotherapeutic purposes. However, the different abilities of first trimester placental chorion mesenchymal stem cells (FCMSCs) and third trimester placental chorion mesenchymal stem cells (TCMSCs) have not yet been explored. In this study, we aimed to compare the effectiveness of FCMSCs and TCMSCs on the treatment of AMI. FCMSCs and TCMSCs were isolated and characterized, and then they were subjected to in vitro endothelial cell (EC) differentiation induction and tube formation to evaluate angiogenic ability. Moreover, the in vivo effects of FCMSCs and TCMSCs on cardiac improvement were also evaluated in a rat MI model. Both FCSMCs and TCMSCs expressed a series of MSCs surface markers. After differentiation induction, FCMSCs-derived EC (FCMSCs-EC) exhibited morphology that was more similar to that of ECs and had higher CD31 and vWF levels than TCMSCs-EC. Furthermore, tube formation could be achieved by FCMSCs-EC that was significantly better than that of TCMSCs-EC. Especially, FCMSCs-EC expressed higher levels of pro-angiogenesis genes, PDGFD, VEGFA, and TNC, and lower levels of anti-angiogenesis genes, SPRY1 and ANGPTL1. In addition, cardiac improvement, indicated by left ventricular end-diastolic diameter (LVEDd), left ventricular end-systolic diameter (LVEDs), left ventricular ejection fraction (LVEF) and left ventricular shortening fraction (LVSF), could be observed following treatment with FCMSCs, and it was superior to that of TCMSCs and Bone marrow MSCs (BMSCs). FCMSCs exhibited a superior ability to generate EC differentiation, as evidenced by in vitro morphology, angiogenic potential and in vivo cardiac function improvement; further, increased levels of expression of pro-angiogenesis genes may be the mechanism by which this effect occurred.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据